Double maintains 1 strategies that include ALDX - Aldeyra Therapeutics, Inc.
Yahoo
As the U.S. stock market experiences a rally fueled by optimism over U.S.-China trade talks and robust corporate earnings, investors are increasingly exploring diverse investment opportunities. Penny stocks, a term that may seem outdated yet remains relevant, represent shares of smaller or newer companies that can offer significant growth potential when backed by strong financial health. In this article, we will explore several penny stocks that demonstrate balance sheet strength and...
Yahoo
LEXINGTON, Mass., May 29, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced that Todd C. Brady, M.D., Ph.D., President and Chief Executive Officer, will participate in a fireside chat at the 2025 Jefferies Global Healthcare Conference in New York, New York.
Yahoo
Aldeyra Therapeutics, Inc. ( NASDAQ:ALDX ) is possibly approaching a major achievement in its business, so we would...
Finnhub
NEW YORK, May 12, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Aldeyra Therapeutics, Inc. . Such investors are advised to contact Danielle Peyton at...
Yahoo
LEXINGTON, Mass., May 05, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra), a biotechnology company devoted to discovering and developing innovative therapies designed to treat immune-mediated and metabolic diseases, today announced the achievement of the primary endpoint in a Phase 3 randomized, double-masked, vehicle-controlled dry eye chamber trial of 0.25% reproxalap ophthalmic solution, an investigational new drug candidate, for the treatment of dry eye disease. For the prespecifie
Yahoo
LEXINGTON, Mass., May 05, 2025--Aldeyra Therapeutics, Inc. (Nasdaq: ALDX) (Aldeyra) today announced it will host a webcast and conference call on Tuesday, May 6, 2025, at 8:00 a.m. ET to announce topline results from Phase 3 dry eye disease clinical trials of reproxalap. The dial-in numbers are (833) 470-1428 for domestic callers and (404) 975-4839 for international callers. The access code is 127477. A live audio webcast of the conference call will also be accessible from the "Investors & Media
Current Value
$2.851 Year Return
Current Value
$2.851 Year Return
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
MCK | -29.60% | $89.80B | +22.74% | 0.39% |
KR | -26.34% | $43.03B | +28.80% | 1.97% |
COR | -23.74% | $55.56B | +24.55% | 0.74% |
TEF | -21.04% | $29.51B | +15.71% | 5.96% |
CME | -20.85% | $97.17B | +37.77% | 3.95% |
EXC | -20.45% | $43.29B | +23.40% | 3.60% |
DUK | -19.82% | $90.43B | +14.83% | 3.58% |
KO | -19.42% | $310.21B | +14.62% | 2.74% |
PGR | -19.39% | $154.31B | +30.02% | 1.84% |
ED | -19.22% | $36.95B | +12.52% | 3.26% |
CBOE | -19.19% | $23.34B | +31.58% | 1.12% |
FMS | -18.71% | $16.66B | +32.05% | 2.83% |
UL | -18.68% | $154.49B | +12.27% | 3.06% |
NGG | -18.45% | $70.06B | +25.61% | 4.24% |
WCN | -18.07% | $48.92B | +13.42% | 0.65% |
RSG | -16.74% | $77.57B | +32.56% | 0.91% |
VZ | -16.72% | $184.42B | +9.98% | 6.26% |
BTI | -16.67% | $106.86B | +59.05% | 6.30% |
XEL | -16.29% | $39.36B | +24.61% | 3.23% |
VRSK | -16.28% | $43.57B | +18.19% | 0.52% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
IWMY | 37.24% | $109.69M | 1.02% |
VNM | 36.59% | $413.48M | 0.68% |
IWC | 36.33% | $815.56M | 0.6% |
CPRJ | 35.43% | $47.91M | 0.69% |
XRT | 35.08% | $331.61M | 0.35% |
IWM | 34.63% | $63.71B | 0.19% |
VTWO | 34.62% | $12.43B | 0.07% |
XHB | 34.50% | $1.24B | 0.35% |
FXD | 34.45% | $327.38M | 0.61% |
PRFZ | 34.43% | $2.37B | 0.34% |
SCHA | 34.36% | $17.18B | 0.04% |
GSSC | 34.34% | $557.11M | 0.2% |
IWO | 34.32% | $11.49B | 0.24% |
IWN | 34.29% | $11.10B | 0.24% |
VIOV | 34.17% | $1.27B | 0.1% |
DFSV | 34.15% | $4.74B | 0.3% |
IAT | 34.12% | $631.32M | 0.4% |
FYX | 33.76% | $827.39M | 0.6% |
SPSM | 33.74% | $11.29B | 0.03% |
FNDA | 33.69% | $8.30B | 0.25% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
ENZL | 0.09% | $72.87M | 0.5% |
UITB | -0.12% | $2.29B | 0.39% |
IBHE | -0.13% | $565.67M | 0.35% |
SUB | -0.15% | $9.76B | 0.07% |
FXB | -0.16% | $84.45M | 0.4% |
HDV | 0.17% | $11.00B | 0.08% |
BKAG | 0.18% | $1.88B | 0% |
AGGH | -0.23% | $314.94M | 0.29% |
FISR | 0.23% | $417.97M | 0.5% |
GII | -0.28% | $542.12M | 0.4% |
EFAV | 0.30% | $5.51B | 0.2% |
UCON | 0.34% | $2.97B | 0.86% |
KCCA | -0.35% | $98.85M | 0.87% |
CTA | 0.36% | $1.09B | 0.76% |
SPMB | 0.39% | $5.98B | 0.04% |
IBDU | 0.41% | $2.62B | 0.1% |
BIL | 0.41% | $44.06B | 0.1356% |
BIV | -0.46% | $22.77B | 0.03% |
GDXJ | -0.47% | $5.59B | 0.51% |
MMIT | 0.48% | $844.27M | 0.3% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
RXST | 51.35% | $605.90M | -74.33% | 0.00% |
FC | 51.16% | $293.65M | -35.73% | 0.00% |
SN | 42.68% | $12.57B | +15.88% | 0.00% |
VSH | 41.85% | $2.16B | -31.76% | 2.53% |
LOGI | 41.82% | $13.09B | -13.48% | 1.57% |
RGP | 41.06% | $182.87M | -48.03% | 7.66% |
LFUS | 41.03% | $5.55B | -13.78% | 1.23% |
RH | 40.33% | $3.35B | -37.32% | 0.00% |
W | 39.42% | $6.15B | -19.33% | 0.00% |
GAP | 39.33% | $8.34B | -15.50% | 2.86% |
HVT | 39.06% | $321.93M | -23.58% | 6.40% |
UA | 37.80% | $2.80B | -1.20% | 0.00% |
ETD | 37.73% | $683.30M | -3.72% | 5.86% |
SCVL | 37.48% | $547.81M | -46.29% | 2.81% |
TPG | 37.21% | $7.08B | +24.82% | 3.37% |
ICHR | 37.09% | $652.71M | -50.82% | 0.00% |
YETI | 36.82% | $2.61B | -26.24% | 0.00% |
DIOD | 36.65% | $2.36B | -32.21% | 0.00% |
RL | 36.63% | $16.15B | +43.68% | 1.24% |
VPG | 36.55% | $350.13M | -19.82% | 0.00% |
Name | Correlation | Market Cap | Return % (1 Year) | Div Yield % |
---|---|---|---|---|
UTZ | <0.01% | $1.16B | -26.39% | 1.79% |
STN | -<0.01% | $12.23B | +30.55% | 0.57% |
EG | 0.01% | $14.26B | -10.28% | 2.38% |
FSLR | 0.02% | $18.00B | -44.18% | 0.00% |
MRK | -0.03% | $201.69B | -38.31% | 3.88% |
EA | -0.03% | $37.03B | +8.88% | 0.51% |
HAE | -0.04% | $3.44B | -16.78% | 0.00% |
WMG | 0.04% | $13.90B | -12.93% | 2.72% |
PAC | -0.05% | $10.20B | +47.76% | 0.00% |
MNOV | -0.08% | $66.70M | +0.74% | 0.00% |
AIG | 0.10% | $48.64B | +13.02% | 1.88% |
HCA | 0.10% | $88.43B | +7.86% | 0.73% |
REYN | -0.11% | $4.57B | -22.38% | 4.24% |
SUI | -0.12% | $16.01B | +11.28% | 2.99% |
RILY | 0.13% | $92.41M | -86.83% | 0.00% |
HTO | -0.16% | $1.83B | +2.78% | 3.07% |
SAR | -0.16% | - | - | 15.38% |
NEXT | 0.17% | $2.20B | +7.79% | 0.00% |
QTTB | 0.17% | $20.74M | -91.24% | 0.00% |
EW | -0.17% | $44.27B | -14.01% | 0.00% |
Name | Correlation | AUM | Expense Ratio |
---|---|---|---|
BTAL | -42.37% | $297.88M | 1.43% |
VIXY | -30.15% | $178.15M | 0.85% |
IVOL | -24.92% | $357.32M | 1.02% |
NEAR | -22.28% | $3.27B | 0.25% |
STIP | -22.17% | $12.59B | 0.03% |
VTIP | -21.45% | $15.09B | 0.03% |
FXC | -20.75% | $89.34M | 0.4% |
TAIL | -20.45% | $107.71M | 0.59% |
STPZ | -20.11% | $451.37M | 0.2% |
TDTT | -18.70% | $2.58B | 0.18% |
IYK | -17.88% | $1.48B | 0.4% |
MEAR | -15.97% | $1.09B | 0.25% |
DFNM | -15.78% | $1.56B | 0.17% |
SCHO | -15.31% | $10.89B | 0.03% |
CARY | -15.17% | $347.36M | 0.8% |
VUSB | -15.04% | $5.25B | 0.1% |
SHY | -14.20% | $23.87B | 0.15% |
VGSH | -13.95% | $22.42B | 0.03% |
UTWO | -12.99% | $374.45M | 0.15% |
FXY | -12.99% | $855.96M | 0.4% |